Piper Sandler cuts Cooper Companies stock rating on weak results

Piper Sandler downgraded Cooper Companies to Neutral from Overweight and cut its price target to $59 from $86 after flat organic growth in its flagship CooperVision franchise and the company’s fourth guidance reduction in two years. Fiscal Q3 2026 adjusted EPS of $1.15 beat the $1.12 consensus, but revenue of $1.07B missed the $1.10B forecast as weaker sales and channel destocking pressured CooperVision. Shares traded at $63.48, down 22.55% year to date and 10% over the prior week, while Baird also downgraded the company and cut its target to $61.

Analysis

COO’s issue is now less a single-quarter revenue shortfall than a credibility discount: repeated guide resets raise the probability that investors assign a lower terminal growth rate and demand evidence before re-rating the multiple. The key financial sensitivity is operating leverage—flat underlying lens growth against a commercial rebuild can pressure incremental margins even if reported sales recover through channel normalization. A low absolute valuation is therefore not a sufficient catalyst; the market will likely require two consecutive quarters of organic growth and stable guidance before treating the weakness as transitory.

The near-term risk/reward remains asymmetric to the downside over the next 1-3 months because consensus estimates may still embed a relatively quick Americas recovery. Alcon (ALC) and Bausch + Lomb (BLCO) are the most relevant public read-throughs: sustained COO underperformance would suggest share leakage or distribution disruption, while a broad-based slowdown would pressure the category rather than create a clean competitor benefit. BLCO is a less attractive long hedge given its higher balance-sheet sensitivity; ALC offers the cleaner quality/scale offset.

The contrarian setup is that channel destocking can mechanically create an easier comparison and a revenue snapback, making a fresh short vulnerable around the next earnings print. That thesis is falsified if organic CVI growth remains below mid-single digits after inventory headwinds are lapped, or if another guidance revision reveals that the commercial remediation is taking longer than expected. Conversely, a clear sequential improvement in Americas sell-through, coupled with no further margin erosion, would justify closing bearish positioning rather than waiting for a valuation-based rebound.

Key Decisions for Investors

• Maintain an underweight/short bias in COO into the next earnings and guidance update; consider entry on rallies toward $63-$65, targeting $55-$58 over 1-3 months. Risk control: cover above $70 or on evidence of mid-single-digit CVI organic growth with reaffirmed forward guidance.
• For sector-neutral exposure, pair short COO against long ALC in equal dollar amounts for 3-6 months. The trade isolates COO execution risk while retaining ophthalmic-device exposure; exit if ALC’s category commentary indicates broad contact-lens demand deterioration rather than COO-specific share loss.
• Do not buy COO solely on apparent undervaluation. Move it to a watch list for a long only after two conditions are met: channel inventory stops detracting from growth and management demonstrates stable guidance through at least one subsequent quarter.
• Monitor BLCO and ALC quarterly commentary on U.S. contact-lens volumes and distributor inventory as a verification signal. Broad weakness across peers would reduce confidence in the pair trade and argues for lowering gross exposure to the category.